Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE study
Year: 2025
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: Advanced or recurrent endometrial carcinoma (EC) represents a significant clinical challenge. This study aimed to evaluate patient (age and comorbidities) and disease (histological subtypes and stages) characteristics, treatment patterns and survival outcomes in a real-world French healthcare setting. METHODS AND ANALYSIS: In this national, multi-centre, retrospective observational cohort study, 200 patients with advanced or recurrent EC receiving first- or second-line chemotherapy during the year 2019 were analysed. Data collected included baseline characteristics, treatment regimens, real-world progression-free survival (rwPFS) and overall survival (OS). RESULTS: 127 and 73 were included in the first and second lines, respectively. Endometrioid carcinoma was the most represented histological subtype (62.0%). Patients in the first line, of whom 31.5% had FIGO (Fédération Internationale de Gynécologie Obstétrique) IVB disease, mainly received a combination of carboplatin and paclitaxel (78.0%), while 131 patients receiving second-line therapy were mainly administered anthracycline (54.2%). Median rwPFS and OS were, respectively, 8.5 and 13.2 months for patients receiving first-line therapy and 4.0 and 9.4 months for patients receiving second-line therapy. In Cox analyses, a diagnosis of carcinosarcoma, the presence of liver metastases and stage IVB disease were associated with worse survival outcomes for patients recieving first-line chemotherapy. Non-platinum chemotherapy and liver metastases were associated with poorer survival in patients receiving second-line chemotherapy. CONCLUSIONS: This study highlights the landscape of metastatic EC treatment in a real-world French setting before the availability of PD1 inhibitors, emphasising the discrepancy between clinical trial data and real-world outcomes. It underscores the necessity for further real-world studies to complement clinical trials for a comprehensive understanding of metastatic EC management.
Source: BMJ Open
Authors: Jerome Alexandre, Philippe Boudier, Elise Lavit, Bernard Asselain, Sheik Emambux, Dominique Berton, Guillaume Babin, Céline Lescure, Pierre-Etienne Heudel, Hélène Salaun, Nicolas Delanoy, Heba Dawood, Pierre Combe, Delphine Duliège, Frederic Selle, Antoinette Hakmé, Lauren Cagnan, Nicolas Offner, Julie Niogret, Patricia Pautier, Zineb Sellam, Manuel Gomes David, Adrien Monard, Anne-Claire Hardy-Bessard, Charlotte Bellier, Alain Lortholary, Marie Chaix, Philippe Follana, Laura Deiana, Laurène Gavoille, Gregory Manuceau, Sadji Djennaoui, Mathilde Cancel, Elsa Kalbacher, Sixtine De Percin
Institutions: Université Paris Cité, Hôpital Cochin, Institut de Cancérologie Strasbourg, Institut Sainte Catherine, Arcagy Gineco, Centre Hospitalier Universitaire de Poitiers, Institut de Cancérologie de l'Ouest, Université de Bordeaux, Inserm, Institut Bergonié, BoRdeaux Institute of onCology, Centre Eugène Marquis, Centre Léon Bérard, Institut Curie, Hôpital Européen Georges-Pompidou, Centre hospitalier universitaire d'Orléans, Groupe Hospitalier Diaconesses Croix Saint-Simon, Hôpital des Diaconesses, MSD (France), Centre Georges François Leclerc, Institut Gustave Roussy, Hôpital Intercommunal de Créteil, Institut de Cancérologie de Lorraine, Groupe Hospitalier Mutualiste de Grenoble, Centre Oscar Lambret, Hôpital privé du Confluent, CHU Dijon Bourgogne, Centre Antoine Lacassagne, Centre Hospitalier Régional Universitaire de Brest, Centre Hospitalier Victor Dupouy, Hôpital Louis-Mourier, Hôpital Bretonneau, Centre Hospitalier Universitaire de Besançon
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,839
Funder: ARCAGY-GINECO
OpenAlex ID: W4414004666